Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Fruquintinib + Chemotherapy in Neoadjuvant Gastric Cancer
NCT06791083Phase 2Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, envafolimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by The First Hospital of Fujian Medical University. Started Jun 2024; status: recruiting.
02
Drugs
fruquintinibenvafolimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06791083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791083.